Skip to content
thestock.space

Smruthi Organics (BSE: SMRUTHIORG) had a P/E of 24.4× on 6 Nov 2026, below the industry P/E of 28.7×. Its ROCE of 7.1% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit fell 10% and 6.0% a year over 3 years. Its dividend yield is 1.0%, and debt is 0.12× equity. It is a small-cap company with a market cap of ₹182 Cr, ranked 98th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 11% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹144.00
Day high
₹163.20
Day low
₹141.00
Prev. close
₹144.20
Volume
20.1K

Health check

1 good · 1 fair · 4 to check
  • ReturnsBehind

    +10.9% over a year, better than 2 of 7 peers.

  • Price tagIn line

    P/E 24.4 vs industry 28.7.

  • GrowthShrinking

    Sales −10.5%, profit −6.0% a year over 3 years.

  • ProfitabilityWeak

    ROCE 7.1% vs peer median 17.9%.

  • Balance sheetSolid

    Debt 0.12× equity, interest covered 6.9×, Piotroski 7 of 9.

  • Red flags1 to check

    Return on equity is low at 4.7%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹182 Cr, #98 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹112 Cr · profit ₹7 Cr
Market cap
₹182 Cr
Small cap
P/E
24.4
Industry 28.7
Price to book
2.48
Peers 4.99
Dividend yield
1.04%
ROE
4.7%
Peers 14.7%
ROCE
7.1%
Peers 17.9%
Debt to equity
0.12
Debt ₹8.59 Cr
EPS (TTM)
₹6.52
OPM (TTM)
16.6%
Net margin 6.6%
Sales growth
+55.4%
Latest quarter vs a year ago
Profit growth
n/a
Year-ago quarter not reported
Price to sales
1.62
EV/EBITDA 10.1

Strengths and risks

Strengths

  • Quarterly sales up 55.4% on a year ago.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Return on equity is low at 4.7%.

Derived automatically from reported figures. Not a recommendation.

About Smruthi Organics

Smruthi Organics Limited manufactures and markets active pharmaceutical ingredient (API) products to India. The company operates through Bulk Drugs and Drugs Intermediates (API), and Formulation segments. The company provides API for cardiovascular, such as amlodipine besilate, losartan potassium, telmisartan, s - amlodipine besilate, s - amlodipine malelate, and valsartan; for anti diabetic, which comprises metformin HCL, vildagliptin, teneligliptin, and…

Headquarters
Solapur
Employees
261
Sector
Healthcare
ISIN
INE172E01011
Website
smruthiorganics.com

Price range

52 weeks

₹95.00₹175.30

Today

₹141.00₹163.20
Avg volume (3M)
9.5K
1-year return
plus 10.9%
From 52-week high
minus 9.1%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.87%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.30%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.81%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.59%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.93%minus 6.6%
SMRUTHIORGSmruthi Organics159.35plus 10.51%18224.42.487.1%4.7%16.6%−10.5%−6.0%1.04%plus 10.9%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.59%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
18.931.622.329.129.3
18.626.618.325.323.5
0.3543.85.8
1.6%15.9%18.0%13.0%19.8%
0.10000
0.50.70.30.30.3
1.41.51.71.81.6
––−0.5−0–
−1.52.81.61.73.9
29.7%27.8%14.4%38.6%25.1%
−1.12.11.41.12.9
-0.961.801.220.932.51

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
−10.5%
Profit CAGR 3Y
−6.0%
EPS CAGR 3Y
−6.1%
ROE
4.7%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
141127125101
–minus 9.8%minus 1.7%minus 19.1%
13111511387.6
9.8121213.3
7.0%9.4%9.6%13.2%
−0.3−0.3−0.3−1
0.411.50.8
4.65.35.46.3
–−0.3−0−0.5
4.554.94.7
8.1%27.8%27.3%26.6%
4.13.63.63.4
–minus 13.1%minus 0.8%minus 3.9%
3.613.143.112.99

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
11.411.411.411.4
56.758.260.262.1
5.711.916.98.6
31.836.723.221.4
106118112104
38.941.347.449.7
1.91.62.63
0.10.10.20.2
1.70.50.41.7
62.974.761.249
106118112104

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
12.14.41022.3
−10.2−7.2−11.4−8.9
−1.52.71.4−12.1
0.3−0.1−01.3
−9.5−8.2−11.5−8.5
2.6−3.8−1.513.8
−3.4−2.3−1.7−1.7

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you